This company listing is no longer active
0A4X Stock Overview
A clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
DMK Pharmaceuticals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0009 |
| 52 Week High | US$1.03 |
| 52 Week Low | US$0.0001 |
| Beta | 1.35 |
| 11 Month Change | 0% |
| 3 Month Change | -93.02% |
| 1 Year Change | -99.82% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4X | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.5% | 2.2% |
| 1Y | -99.8% | 0.7% | 8.0% |
Return vs Industry: 0A4X underperformed the UK Pharmaceuticals industry which returned -3.2% over the past year.
Return vs Market: 0A4X underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
| 0A4X volatility | |
|---|---|
| 0A4X Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A4X's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0A4X's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | Eddie Glover | www.dmkpharmaceuticals.com |
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
DMK Pharmaceuticals Corporation Fundamentals Summary
| 0A4X fundamental statistics | |
|---|---|
| Market cap | US$10.00 |
| Earnings (TTM) | -US$21.33m |
| Revenue (TTM) | US$3.62m |
0.0x
P/S Ratio0.0x
P/E RatioIs 0A4X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4X income statement (TTM) | |
|---|---|
| Revenue | US$3.62m |
| Cost of Revenue | US$4.97m |
| Gross Profit | -US$1.35m |
| Other Expenses | US$19.98m |
| Earnings | -US$21.33m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.11 |
| Gross Margin | -37.30% |
| Net Profit Margin | -589.28% |
| Debt/Equity Ratio | 0% |
How did 0A4X perform over the long term?
See historical performance and comparison